CDF Partners with Mediaplanet for Morning Nutrition Campaign
The Celiac Disease Foundation is proud to partner with Mediaplanet for their Morning Nutrition campaign.
Continue ReadingThe Celiac Disease Foundation is proud to partner with Mediaplanet for their Morning Nutrition campaign.
Continue ReadingToday, the U.S. Food and Drug Administration issued a final rule for gluten-free labeling compliance requirements for fermented and hydrolyzed foods.
Continue ReadingCDF has been approved for a $100,000 funding award through the Eugene Washington PCORI Engagement Awards program. The funds will support the community convening of patient advocates, researchers, and other key stakeholders to create a roadmap for patient advocate engagement in research.
Continue ReadingEach year, we proudly embrace the unity and generosity of our community during May Celiac Disease Awareness Month.
Continue ReadingMore and more evidence is showing what many have long suspected: maintaining a truly gluten-free diet may not be possible.
Continue ReadingOn December 11, 2019, CEO Marilyn G. Geller was with Senator Blumenthal's legislative staff as Senator Richard Blumenthal (D-CT) introduced S.3021: Gluten in Medicine Disclosure Act of 2019 to the Senate. The Celiac Disease Foundation is proud to be a partner in this effort.
Continue ReadingResearchers at the Beth Israel Deaconess Medical Center, including Celiac Disease Foundation Medical Advisory Board Member Dan Leffler, conducted a study to determine the effects of the gluten-free diet (GFD)…
Continue ReadingScientist at Cincinnati Children’s Hospital awarded $1.5 million grant to study stem cells from patients with genetic diseases, including celiac disease, that impair one’s ability to properly absorb nutrients to help develop new therapies for malnutrition.
Continue ReadingMany people who suspect they have celiac disease choose to start a gluten-free diet right away, without a formal diagnosis. Here's why you shouldn't.
Continue ReadingActoBio announces FDA has given permission to an Investigational New Drug (IND) application for Actobiotics® AG017, a therapeutic candidate for celiac disease.
Continue Reading